Join our $10M Gains for Good challenge!

Daffy

Alzheimer's Drug Discovery Foundation

Alzheimer's Drug Discovery Foundation

New York, NY 10019
Tax ID20-1082179

Want to make a donation using Daffy?

Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.

Payment method

Frequency

Amount

$USD
Daffy covers all ACH transaction fees so 100% of your donation goes to your favorite charities.

Do you work for Alzheimer's Drug Discovery Foundation? Learn more here.

By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.

About this organization

Revenue

$55,817,240

Expenses

$16,190,686

Mission

The mission of the Alzheimer's Drug Discovery Foundation is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

About

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer's. The ADDF focuses on translating the knowledge we have gained about the causes of Alzheimer's disease into drugs to conquer it. We support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the "valley of death" because it's where good ideas go to die. These projects hold great promise, but also great risk. And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer's disease that would otherwise go unexplored. Today, Alzheimer's disease affects more than 50 million people and is the only top 10 cause of death that cannot be prevented, cured or slowed. But we have the power to stop this devastating disease in its tracks. By advancing the most promising research across the globe, we will conquer Alzheimer's disease.

Interesting data from their 2020 990 filing

The filing clearly states the mission of the non-profit as “Accelerate the discovery of drugs to prevent and treat alzheimer's disease and related dementias.”.

When outlining its functions, they were explained as: “Accelerate the discovery of drugs to prevent and treat alzheimer's disease and related dementias.”.

  • In compliance with legal regulations, the non-profit has reported their state of operation as DE.
  • The filing records the non-profit's address for 2020 as 57 WEST 57TH ST 904, NEW YORK, NY, 10019.
  • As of 2020, the non-profit's form reports a total of 10 employees.
  • Does not operate a hospital.
  • Does not operate a school.
  • Does not collect art.
  • Does not provide credit counseling.
  • Has foreign activities.
  • Is not a donor-advised fund.
  • Is not a private foundation.
  • Expenses are greater than $1,000,000.
  • Revenue is greater than $1,000,000.
  • Revenue less expenses is $39,626,554.
  • The compensation of the CEO of the organization is not based on an independent review and approval process.
  • The organization elects its board members.
  • The organization has a written policy that describes how long it will retain documents.
  • The organization has 19 independent voting members.
  • The organization was formed in 2004.
  • The organization has a written policy that addresses conflicts of interest.
  • The organization is required to file Schedule B.
  • The organization is required to file Schedule J.
  • The organization is required to file Schedule O.
  • The organization pays $1,150,897 in salary, compensation, and benefits to its employees.
  • The organization pays $1 in fundraising expenses.
  • The organization provides Form 990 to its governing body.
  • The organization has minutes of its meetings.
  • The organization has a written whistleblower policy.
  • The organization has fundraising events.
  • The organization has grants to organizations.
  • The organization's financial statements were reviewed by an accountant.